Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Quantum Biopharma (QNTM) Receivables - Net (2018 - 2025)

Quantum Biopharma recorded quarterly Receivables - Net of $231053.0 in Q4 2025, down 38.33% quarter-over-quarter from $374678.0 in Q4 2024, and down 38.33% year-over-year from $374678.0 in Q4 2024.

Quantum Biopharma's Receivables - Net history runs 8 years deep, the most recent figure standing at $231053.0 for Q4 2025.

  • In Q4 2025, Receivables - Net fell 38.33% year-over-year to $231053.0; the TTM figure through Dec 2025 stood at $231053.0 (down 38.33% YoY), while the FY2025 annual figure was $231053.0, down 38.33% from the prior year.
  • Receivables - Net came in at $231053.0 for Q4 2025 at Quantum Biopharma, down from $374678.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $500964.0 in Q4 2021 to a low of -$341916.0 in Q2 2021.
  • A 5-year average of $138364.0 and a median of $229908.5 in 2023 frame the typical range for Receivables - Net.
  • On a YoY basis, Receivables - Net climbed as much as 210.5% in 2021 and fell as far as 170.39% in 2021.
  • Quantum Biopharma's Receivables - Net stood at $500964.0 in 2021, then declined by 25.27% to $374377.0 in 2022, then sank by 38.89% to $228764.0 in 2023, then jumped by 63.78% to $374678.0 in 2024, then sank by 38.33% to $231053.0 in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods registered $231053.0, $374678.0, and $228764.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 231,053.00
Dec 31, 2025 231,053.00
Dec 31, 2024 374,678.00
Dec 31, 2024 374,678.00
Dec 31, 2023 228,764.00
Dec 31, 2023 228,764.00
Dec 31, 2022 374,377.00
Dec 31, 2022 374,377.00
Dec 31, 2021 500,964.00
Dec 31, 2021 500,964.00
Sep 30, 2021 -208,114.00
Sep 30, 2021 -208,114.00
Jun 30, 2021 -341,916.00
Jun 30, 2021 -341,916.00
Mar 31, 2021 -52,894.00
Mar 31, 2021 -52,894.00
Dec 31, 2020 161,342.00
Dec 31, 2020 161,342.00
Jun 30, 2020 485,760.43
Jun 30, 2020 485,760.43
Mar 31, 2020 -444,605.39
Mar 31, 2020 -444,605.39
Dec 31, 2019 1.57 Mn
Dec 31, 2019 1.57 Mn
Mar 31, 2019 124,156.46
Mar 31, 2019 124,156.46
Dec 31, 2018 750,792.12
Dec 31, 2018 750,792.12